when was semaglutide fda approved U.S. | The FDA has a new higher dose (7.2 mg) of Wegovy ( semaglutide) injection, Wegovy HD, for weight loss and long-term weight FDA Warns on Certain Forms

It is important for patients to take the medication as directed by their healthcare provider to ensure optimal results

Mounjaro (Tirzepatide) Dual action: targets both GLP-1 and GIP receptors Strong appetite suppression & improved blood sugar control Clinical trials show average body weight loss up to 22.5% over 72 weeks Wegovy (Semaglutide) Targets GLP-1 receptors only Licensed in the UK for obesity and cardiovascular protection STEP trials show 1521% body weight loss A new 7.2mg dose is expected in late 2025, with results potentially matching Mounjaro Both treatments are once-weekly injections, prescribed alongside healthy diet and lifestyle changes

Humira (adalimumab) Disease area(s): Immunology Manufacturer(s): AbbVie 2024 Sales (USD): $8.99 billion Why it sold so well: In 2024, Humira remained a significant revenue contributor for AbbVie, despite facing substantial declines due to biosimilar competition following its US loss of exclusivity in January 2023

If the patient is experiencing gastrointestinal symptoms, EMS personnel should assess for recent increase in dose with their prescribed semaglutide medications, as increasing the dose of semaglutide medications may trigger gastrointestinal symptoms